New test aims to tailor breast cancer treatment, reduce side effects
Diagnosis
Recruiting now
This study is testing whether a diagnostic tool called HER2DX can help doctors choose the best treatment for people with early-stage HER2-positive breast cancer. About 304 participants will be randomly assigned to receive either standard treatment or treatment guided by the HER2D…
Phase: NA • Sponsor: Fundacio Clinic Barcelona • Aim: Diagnosis
Last updated Mar 30, 2026 14:32 UTC